<DOC>
	<DOCNO>NCT00495014</DOCNO>
	<brief_summary>This study represent second Phase 1 study GSK376501 goal evaluate safety tolerability . The way human body process GSK376501 also determine .</brief_summary>
	<brief_title>Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>The subject healthy overweight/obese , define body mass index great 25 less 35kg/m2 , inclusive . The subject adult male female nonchildbearing potential age 18 65 year , inclusive , time signing informed consent . The subject partner willing use doublebarrier method contraception first day study drug administration 5 halflives drug elapse follow last day study drug administration . The subject demonstrate ECG value within range specify protocol screen baseline . The subject capable give write informed consent , include ability read , comprehend comply protocol requirement restriction describe consent form . Has know immediate delay hypersensitivity reaction idiosyncrasy medication chemically related study drug history drug allergy , opinion physician responsible , contraindicate participation study . Has know allergy tablet formulation excipients GSK376501 pioglitazone ( applicable ) . Has sensitivity heparin history heparininduced thrombocytopenia . Has history alcohol abuse dependence within 12 month prior study . Has positive alcohol test screen baseline and/or unwilling abstain alcohol 72 hour prior start dose discharge clinic 72 hour prior followup visit . Is unwilling abstain caffeine xanthinecontaining product 24 hour prior dose throughout inhouse period , 24 hour prior followup visit . The subject smoke use tobacco nicotinecontaining product within 6 month prior study , positive urine cotinine screen baseline . Is unwilling refrain use tobacco illicit drug trial , and/or test positive urine cotinine drug abuse screen baseline . At minimum , list drug class drug screen include follow : amphetamine , barbiturate , benzoylecgonine , benzodiazepine , cannabinoids , cotinine , opiates . Where participation study would result donation blood excess 500 ml within 56 day period . Has systolic blood pressure outside range 140 90mmHg , diastolic blood pressure outside range 90 60mmHg and/or heart rate outside range 90 45bpm , inclusive , screen baseline . Experiencing clinically significant ECG abnormality screen baseline . Has history current evidence positive HIV test . Has history positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Has laboratory safety screen test outside range specify protocol screen baseline . T. Pregnant lactate woman , woman childbearing potential . Has history rhabdomyolysis . Has congestive heart failure history congestive heart failure New York Heart Association Class IIV symptom Has history thyroid dysfunction abnormal thyroid function test assess TSH screening . Has history current evidence sleep apnea . Has previous exposure GSK376501 , exception subject randomize previously complete study GSK376501 may participate cohort evaluate pioglitazone . Has treatment new molecular entity ( investigational drug ) previous 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) , prior first dose current study medication . For purpose study , new molecular entity define compound yet reach Phase 3 development . The washout define last dose study medication previous study first dose study drug . Has expose four new molecular entity within 12 month prior first dose day . Has use follow prescription nonprescription medication within 14 day 5 half life , whichever longer , prior first dose study medication : vitamin ( dose great recommended daily allowance ) , dietary herbal supplement , include St. John 's Wort . Is unable unwilling discontinue use acetaminophen 72 hour prior dose throughout inhouse period use within 72 hour followup visit . Requires use prohibited medication . Is unable unwilling abstain consumption grapefruit grapefruit juice 7 day prior first dose study medication final pharmacokinetic sample collect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>GSK376501 ,</keyword>
	<keyword>Single Dose ,</keyword>
	<keyword>Dose Escalation ,</keyword>
	<keyword>Healthy Overweight/Obese Volunteer</keyword>
</DOC>